Search
Paritaprevir
go.drugbank.com/drugs/DB09297ApprovedInvestigationalParitaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … First approved in December 2014, Viekira Pak is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with [DB00811] for the treatment of HCV
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseTaletrectinib
go.drugbank.com/drugs/DB18711ApprovedInvestigationalTaletrectinib is an orally available small molecule kinase inhibitor. … [A274158] As part of the second-generation of ROS1 inhibitors, taletrectinib is significantly more potent against ROS1 resistance mutations - for example, the IC50 for taletrectinib against ROS1 exhibiting
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsCalaspargase pegol
go.drugbank.com/drugs/DB14730ApprovedInvestigationalCalaspargase pegol, also known as _asparlas_, is an asparagine specific enzyme which is indicated as a part of a multi-agent chemotherapy regimen for the treatment of ALL [L4890]. … Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) [A40270].
Abrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigationalAbrocitinib is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). … [A244549] Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy.
Categories: Agents for Dermatitis, Excluding Corticosteroids, Cytochrome P-450 SubstratesSynonyms: PF-04965842Profenamine
go.drugbank.com/drugs/DB00392ApprovedIt is primarily used as an antidyskinetic to treat Parkinsonism. It is sold under the trade name Parsitan in Canada.[L46812] In the US, the marketing of profenamine has been discontinued.[L46817]
Categories: NMDA Receptor AntagonistsIvacaftor
go.drugbank.com/drugs/DB08820ApprovedInvestigational[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein … , an ion channel involved in the transport of chloride and sodium ions across cell membranes.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesPrimaquine
go.drugbank.com/drugs/DB01087ApprovedInvestigationalIt has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. … An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide.
Categories: Antibiotics for Pneumocystis Pneumonia, P-glycoprotein inhibitorsCholine C 11
go.drugbank.com/drugs/DB09277ApprovedCholine C 11 is a marker for cellular proliferation as its main molecule is a precursor for the biosynthesis of phospholipids which are essential components of all cell membranes.
Tofersen
go.drugbank.com/drugs/DB14782ApprovedInvestigational[L46133] In June of 2024, it was additionally approved by the EMA for the same indication. … Tofersen is under an intrathecally administered antisense oligonucleotide targeting the mutated SOD1 gene that causes amyotrophic lateral sclerosis (ALS).
Alfacalcidol
go.drugbank.com/drugs/DB01436ApprovedInvestigationalNutraceutical[A234044] It plays an essential function in calcium homeostasis and bone metabolism. … [L33284] In approving European countries, alfacalcidol is also indicated for managing nutritional and malabsorptive rickets and osteomalacia, vitamin D-dependent rickets and osteomalacia, and hypophosphataemic
Categories: Drugs for Treatment of Bone Diseases